002898.SZ Stock Analysis
00
Uncovered
Sailong Pharmaceutical Group Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Sailong Pharmaceutical Group Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical intermediates, raw materials, and preparations. The company is headquartered in Zhuhai, Guangdong and currently employs 405 full-time employees. The company went IPO on 2017-09-12. The Company’s main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The firm mainly conducts its businesses with domestic market.